Addex Pharmaceuticals, a developer of drugs for Central Nervous System (CNS) disorders, has landed $32 million in its third round of venture capital. GSK's venture capital division SR One led the round. Additional investors included the Roche Venture Fund, Sofinnova Partners, Index Ventures, TVM Capital, PolyTechnos Venture-Partners, Bio*One Capital, Renaissance PME and Varuma. This brings the company's venture capital total to $81 million since 2002. The funding will be used to develop Addex's clinical and pre-clinical drug candidates, including ADX10059, which is currently in Phase II testing for acute migraine and gastro oesophageal reflux disease (GERD).
- see the press release from Addex's Web site